CAMBRIDGE, Mass., April 7,
2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL), a
clinical stage biopharmaceutical company focused on creating
precisely targeted therapies for clinically proven kinase
targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer,
will participate in a virtual fireside chat during the 2022
Canaccord Genuity Horizons in Oncology Virtual Conference on
Thursday, April 14, 2022, at
9:00 a.m. ET.
A live webcast will be available in the investor section of the
company's website at www.nuvalent.com, and archived for 30 days
following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical stage
biopharmaceutical company focused on creating precisely
targeted therapies for patients with cancer, designed to overcome
the limitations of existing therapies for clinically proven kinase
targets. Leveraging deep expertise in chemistry and structure-based
drug design, we develop innovative small molecules that have the
potential to overcome resistance, minimize adverse events, address
brain metastases, and drive more durable responses. Nuvalent is
advancing a robust pipeline with parallel lead programs in
ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC),
along with multiple discovery-stage research programs. We routinely
post information that may be important to investors on our website
at www.nuvalent.com. Follow us on Twitter (@nuvalent) and
LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-2022-canaccord-genuity-horizons-in-oncology-virtual-conference-301519585.html
SOURCE Nuvalent, Inc.